PaySign, Inc. (PAYS)

Over the past six months, PaySign's stock has seen significant movement, with a reported increase of 146.84%. On August 5, 2025, PaySign reported its Q2 earnings after the market close, reporting $0.02 EPS, missing the consensus estimate of $0.04, and PAYS shares declined by 26.7% the next day. The company reported record revenue of $19.1 million, a 33% increase year-over-year. Gross margins improved by 870 basis points to 61.6%. Adjusted EBITDA doubled to $4.5 million, a 102% increase from Q2 2024. The patient affordability business showed remarkable growth, with revenue increasing by 190% year-over-year to $7.75 million. PaySign successfully onboarded 123 out of 132 awarded plasma centers, increasing its market share to approximately 50%. As of October 27, 2025, the stock price was $5.85, showing a 56.42% increase over the last year.

The provided information does not explicitly detail demand seasonality for PaySign, Inc.'s products and services. However, the company's focus on healthcare-related payments and corporate incentive programs suggests that demand might be influenced by factors such as healthcare industry trends, pharmaceutical program cycles, and corporate budgeting for rewards and incentives. Some seasonality in its business might exist, but the specifics are not provided.

PaySign, Inc. is a financial technology company specializing in prepaid card programs and processing services, operating within the Commercial Services, Financials, and Technology sectors. Its core business revolves around its proprietary card-processing platform, facilitating services such as transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service. Major products and services include prepaid card programs, patient affordability offerings, digital banking services, donor compensation, integrated payment processing services, and per diem/corporate expense payments.

PaySign, Inc. is headquartered in Henderson, Nevada, United States. Its operations extend across corporate, consumer, and government sectors, serving companies and municipalities, but a specific global or national geographic footprint beyond its headquarters is not detailed.

PaySign's brand reputation in the past year appears to be generally positive, particularly in its niche markets and for its operational efficiency and innovation. The company is recognized as a market leader in plasma donation cards and pharmaceutical affordability/benefit cards. Recent reports highlight strong revenue growth, particularly in the patient affordability business, and successful expansion strategies. Analysts have a "Moderate Buy" consensus rating for PaySign, with an average price target suggesting a significant upside.

PaySign, Inc. has a mix of institutional and individual ownership, with a notable insider presence. As of October 7, 2025, PaySign, Inc. has 198 institutional owners holding a total of 21,880,222 shares. Major institutional shareholders include Topline Capital Management, LLC, BlackRock, Inc., Vanguard Group Inc, Renaissance Technologies Llc, 1248 Management, LLC, Geode Capital Management, Llc, and State Street Corp. Insiders own a significant portion of the company, with Mark Newcomer, the CEO and founder, being the largest individual shareholder, owning 26,030,728 shares, representing 47.81% of the company.